Bicycle Therapeutics
BCYC
101 hedge funds and large institutions have $651M invested in Bicycle Therapeutics in 2023 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 7 closing their positions.
243% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 7
57% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 23
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more funds holding
Funds holding: 85 → 101 (+16)
7.54% more ownership
Funds ownership: 80.75% → 88.29% (+7.5%)
5% more capital invested
Capital invested by funds: $618M → $651M (+$32.8M)
47% less call options, than puts
Call options by funds: $2.04M | Put options by funds: $3.84M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$37.9M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$29.5M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$23.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.8M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$13.3M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$8.47M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$5.18M |
| 4 |
SCM
Sio Capital Management
New York
|
-$3.93M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$2.86M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Wells Fargo
San Francisco,
California
| $241 | +$274 | +12 | New |
|
|
LGM
102
Logos Global Management
San Francisco,
California
| – | -$13.3M | -520,000 | Closed |
|
|
IC
103
Ikarian Capital
Dallas,
Texas
| – | -$5.18M | -203,037 | Closed |
|
|
ECM
104
ExodusPoint Capital Management
New York
| – | -$2.86M | -111,973 | Closed |
|
|
BFM
105
Boothbay Fund Management
New York
| – | -$1.08M | -42,133 | Closed |
|
106
Goldman Sachs
New York
| – | -$465K | -18,215 | Closed |
|
107
Marshall Wace
London,
United Kingdom
| – | -$237K | -9,271 | Closed |
|
|
PCM
108
Prelude Capital Management
New York
| – | -$231K | -9,061 | Closed |
|
BCYC Hedge Fund Activity: Q3 2023 in Review
101 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q3 2023, worth a combined $651M — up 5.3% from $618M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new BCYC positions and 7 closed out — a net gain of 17 holders — while 36 added to existing stakes and 23 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $37.9M. The largest seller was Logos Global Management, exiting entirely with an estimated $13.3M sold.
- 101 institutional investors held Bicycle Therapeutics (BCYC) as of Q3 2023, up from 85 in Q2 2023.
- Funds reported $651M of Bicycle Therapeutics stock for Q3 2023, up 5.3% quarter-over-quarter.
- 24 funds opened new Bicycle Therapeutics positions in Q3 2023 and 7 closed out, a net change of +17 holders.
- The largest Bicycle Therapeutics buyer in Q3 2023 was Paradigm Biocapital Advisors, an estimated $37.9M added.
- The largest Bicycle Therapeutics seller in Q3 2023 was Logos Global Management, an estimated $13.3M sold.
Based on aggregated 13F filings for Q3 2023.